Estimated GFR decline as a surrogate end point for kidney failure: a post hoc analysis from the Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan (RENAAL) study and Irbesartan Diabetic Nephropathy (Q86692459)
Jump to navigation
Jump to search
scientific article published on 06 November 2013
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Estimated GFR decline as a surrogate end point for kidney failure: a post hoc analysis from the Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan (RENAAL) study and Irbesartan Diabetic Nephropathy |
scientific article published on 06 November 2013 |
Statements
Estimated GFR decline as a surrogate end point for kidney failure: a post hoc analysis from the Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan (RENAAL) study and Irbesartan Diabetic Nephropathy Trial (IDNT) (English)
Hiddo J Lambers Heerspink
Lesley A Inker
Ron Gansevoort
Hans-Henrik Parving
Jamie P Dwyer
Hasi Mondal
Tom Greene
Andrew S Levey
Dick de Zeeuw
6 November 2013